PMID- 32452532
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210106
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 61
IP  - 6
DP  - 2020 Jun
TI  - Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
PG  - 1090-1098
LID - 10.1111/epi.16546 [doi]
AB  - OBJECTIVE: To evaluate the potential impact of concomitant clobazam (CLB) use on 
      the efficacy of cannabidiol (CBD) treatment in patients with Dravet syndrome and 
      Lennox-Gastaut syndrome using meta-analytical techniques. METHODS: We searched 
      for randomized, placebo-controlled, single- or double-blinded trials. The 
      proportion of patients who achieved >/=50% reduction from baseline in seizure 
      frequency during the treatment period was assessed according to CLB status. Risk 
      ratios (RRs) with 95% confidence intervals (CIs) were estimated. RESULTS: Four 
      trials were included and enrolled 714 participants, 429 for the add-on CBD group 
      and 285 for the add-on placebo group. Among CBD-treated patients, 240 (55.9%) 
      were taking concomitant CLB (CLB-On) and 189 (44.1%) were not taking concomitant 
      CLB (CLB-Off); in placebo-treated patients, 158 (55.4%) were CLB-On and 127 
      (44.6%) CLB-Off. The percentages of patients who had at least 50% reduction in 
      seizure frequency during the treatment period were 29.1% in the CBD arm and 15.7% 
      in the placebo group among CLB-Off patients (RR = 1.80, 95% CI = 1.12-2.90, 
      P = .015). Among CBL-On patients, the >/=50% reduction in seizure frequency was 
      found in 52.9% and 27.8% in the CBD and placebo groups, respectively (RR = 1.85, 
      95% CI = 1.40-2.44, P < .001). SIGNIFICANCE: CBD was associated with a higher 
      rate of seizure response in comparison to placebo when added to the existing 
      antiepileptic regimen both in patients taking and in those not taking concomitant 
      CLB. The lack of randomization for CLB status and the limited sample size need to 
      be considered in the interpretation of the findings.
CI  - (c) 2020 International League Against Epilepsy.
FAU - Lattanzi, Simona
AU  - Lattanzi S
AUID- ORCID: 0000-0001-8748-0083
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Trinka, Eugen
AU  - Trinka E
AD  - Department of Neurology, Christian Doppler Clinic, Paracelsus Medical University, 
      Salzburg, Austria.
AD  - Center for Cognitive Neuroscience, Salzburg, Austria.
AD  - Public Health, Health Services Research, and Health Technology Assessment, 
      University for Health Sciences, Medical Informatics, and Technology, Hall in 
      Tyrol, Austria.
FAU - Striano, Pasquale
AU  - Striano P
AUID- ORCID: 0000-0002-6065-1476
AD  - Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, 
      Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, G. Gaslini 
      Institute, University of Genoa, Genoa, Italy.
FAU - Zaccara, Gaetano
AU  - Zaccara G
AD  - Health Agency of Tuscany, Florence, Italy.
FAU - Del Giovane, Cinzia
AU  - Del Giovane C
AD  - Institute of Primary Health Care, Bernese Institute of Family Medicine, 
      University of Bern, Bern, Switzerland.
FAU - Nardone, Raffaele
AU  - Nardone R
AD  - Department of Neurology, Christian Doppler Clinic, Paracelsus Medical University, 
      Salzburg, Austria.
AD  - Department of Neuroscience, Biomedicine, and Movement Science, University of 
      Verona, Verona, Italy.
FAU - Silvestrini, Mauro
AU  - Silvestrini M
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Brigo, Francesco
AU  - Brigo F
AUID- ORCID: 0000-0003-0928-1577
AD  - Department of Neuroscience, Biomedicine, and Movement Science, University of 
      Verona, Verona, Italy.
AD  - Division of Neurology, Franz Tappeiner Hospital, Merano, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200526
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Anticonvulsants)
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 2MRO291B4U (Clobazam)
SB  - IM
CIN - Epilepsia. 2020 Aug;61(8):1795-1796. PMID: 32662877
MH  - Anticonvulsants/*administration & dosage/blood
MH  - Cannabidiol/*administration & dosage/blood
MH  - Clobazam/*administration & dosage/blood
MH  - Drug Therapy, Combination
MH  - Epilepsies, Myoclonic/blood/drug therapy
MH  - Humans
MH  - Lennox Gastaut Syndrome/blood/drug therapy
MH  - Randomized Controlled Trials as Topic/methods
MH  - Seizures/blood/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Dravet syndrome
OT  - Lennox-Gastaut syndrome
OT  - cannabidiol
OT  - clobazam
OT  - epilepsy
EDAT- 2020/05/27 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/05/27 06:00
PHST- 2020/03/07 00:00 [received]
PHST- 2020/04/26 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/05/27 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/05/27 06:00 [entrez]
AID - 10.1111/epi.16546 [doi]
PST - ppublish
SO  - Epilepsia. 2020 Jun;61(6):1090-1098. doi: 10.1111/epi.16546. Epub 2020 May 26.